Optimizing the Use of Bispecific Antibodies in Hematologic Malignancies

Immunotherapy using antibody drug conjugates, immune check point inhibitors, and chimeric antigen receptor (CAR) T-cells has significantly transformed the treatment landscape of relapsed or refractory hematologic malignancies. Bispecific antibodies represent a novel immunotherapy approach with remarkable efficacy for the treatment of relapsed/refractory hematologic malignancies. However, they also have a distinct toxicity profile associated with T-cell activation.  There is a clear need to educate clinicians about the special considerations associated with the use of bispecific antibodies in appropriately selected patients.

Target Audience

This program is designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, physician assistants, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Following this program, participants should be able to:

  • Review the safety data from clinical trials that have evaluated bispecific antibodies in patients with hematologic malignancies.
  • Recognize the toxicities associated with bispecific antibodies and develop an appropriate supportive care intervention for the management of adverse events.

You may also be interested in

NCCN Guidelines® Insights - Management of Immunotherapy-Related Toxicities, Version 2.2024
These NCCN Guidelines Insights highlight recent guideline updates pertaining to the management of emerging toxicities related to cancer immunotherapy.
Team-Based Management of Immunotherapy-Related Toxicities
Continuing education on the importance of early recognition and management of immunotherapy-related toxicities and involvement of the multidisciplinary team will be crucial to ensure optimal outcomes for patients with cancer.
Additional information
Supporters: 

This activity is supported by educational grants from AstraZeneca; Geron; Ipsen Biopharmaceuticals, Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Lilly; Menarini-Stemline; Novartis; Sanofi; and Taiho Oncology, Inc. This educational activity is supported by independent medical educational grants from AbbVie; ADC Therapeutics; and GSK. This activity is supported by independent educational grants from Daiichi Sankyo; Incyte Corporation; and Rigel Pharmaceuticals, Inc. This activity is supported by a grant from Pfizer Inc.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
    • 1.00 ANCC Pharmacology Contact Hours
  • 1.00 Participation
Course opens: 
12/01/2024
Course expires: 
12/01/2025
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 2024 Annual Congress: Hematologic Malignancies™

Jennifer Crombie, MD
Dana-Farber/Brigham and Women's Cancer Center

Bernard L. Marini, PharmD, BCOP
University of Michigan Rogel Cancer Center

Kathy Mooney, MSN, RN, ACNS-BC, BMTCN, OCN
Johns Hopkins Kimmel Cancer Center

Tarun Wasil, MD
New York Cancer & Blood Specialists

 

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Jennifer Crombie, MD
AbbVie, Inc.: Consulting Fee; Grant/Research Support
ADC Therapeutics: Consulting Fee
Bayer HealthCare: Grant/Research Support
Genentech/Roche: Consulting Fee
GenMab: Consulting Fee
Merck & Co., Inc.: Grant/Research Support
Regeneron Pharmaceuticals, Inc.: Consulting Fee
SeaGen: Consulting Fee 

Bernard L. Marini, PharmD, BCOP (also a member of the Congress Planning Committee)
Servier: Consulting Fee 

Kathy Mooney, MSN, RN, ACNS-BC, BMTCN, OCN
Johnson & Johnson: Consulting Fee
Kite Pharma: Product/Speakers Bureau

Tarun Wasil, MD
AstraZeneca Pharmaceuticals LP: Consulting Fee
BeiGene: Consulting Fee
Eli Lilly and Company: Consulting Fee
GSK: Consulting Fee
Pfizer Inc.: Consulting Fee

Congress Planning Committee Disclosures

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Gabriela S. Hobbs, MD
AbbVie, Inc.: Scientific Advisor
Bristol Myers Squibb: Scientific Advisor
Cogent Biosciences, Inc.: Consulting Fee
Incyte Corporation: Grant/Research Support; Scientific Advisor
MorphoSys AG: Consulting Fee
Novartis Pharmaceuticals Corporation: Scientific Advisor
Pfizer Inc.: Consulting Fee
PharmaEssentia USA Corporation: Consulting Fee
Regeneron Pharmaceuticals: Equity Interest/Stock Options

Shaji K. Kumar, MD
AbbVie, Inc.: Grant/Research Support; Scientific Advisor
Amgen Inc.: Grant/Research Support; Scientific Advisor
BeiGene: Honoraria
Bristol-Myers Squibb: Grant/Research Support; Scientific Advisor
CARsgen Therapeutics: Grant/Research Support
GSK: Grant/Research Support; Scientific Advisor
Janssen Pharmaceutica Products, LP: Grant/Research Support; Scientific Advisor
Moderna, Inc.: Consulting Fee
Oricell Therapeutics: Grant/Research Support
Pfizer Inc.: Consulting Fee
Regeneron Pharmaceuticals, Inc.: Grant/Research Support; Scientific Advisor
Roche Laboratories, Inc.: Grant/Research Support; Scientific Advisor
sanofi-aventis U.S.: Grant/Research Support; Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support; Scientific Advisor

MiKaela M. Olsen, DNP, APRN-CNS, AOCNS, FAAN
BD: Consulting Fee; Honoraria

Andrew D. Zelenetz, MD, PhD
AbbVie, Inc.: Consulting Fee
Adaptive Biotechnologies: Scientific Advisor
ADC Therapeutics: Scientific Advisor
Amgen Inc.: Consulting Fee
Arvinas: Consulting Fee; Scientific Advisor
AstraZeneca Pharmaceuticals LP: Consulting Fee
BeiGene: Consulting Fee; Grant/Research Support
Bristol Myers Squibb: Consulting Fee
Eli Lilly and Company: Consulting Fee; Scientific Advisor
Genentech, Inc.: Consulting Fee; Grant/Research Support
Gilead Sciences, Inc.: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee
MEI Pharma Inc.: Consulting Fee; Grant/Research Support
MorphoSys AG: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Roche Laboratories, Inc.: Consulting Fee; Grant/Research Support

NCCN Staff Disclosures

None of the other planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour, 1.0 of which are pharmacotherapeutic contact hours.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-24-123-H01-P

PAs
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until December 1, 2025. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
    • 1.00 ANCC Pharmacology Contact Hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing